The International Gaucher Alliance and Kantar Health Launch the GARDIAN Registry to Accelerate the Understanding of Neuronopathic Gaucher Disease

NEW YORK–(BUSINESS WIRE)–The International Gaucher Alliance (IGA) and Kantar Health announce today the launch of the disease registry GARDIAN: Gaucher Registry for Development Innovation and Analysis of Neuronopathic Disease. This launch follows the announcement of the IGA and Kantar Health collaboration in 2020.

Gaucher Disease (GD) is an autosomal recessive disease and the most common Lysosomal Storage Disorder, with an incidence of about 1 in 100,000 live births. Three types exist: type I, the most common, and types II and III, also called neuronopathic GD (nGD). Type II (GD2) is characterized by rapidly progressive neurological symptoms in babies; whereas type III (GD3) appears later in childhood and is defined by slower progression of neurological symptoms. Today, GD has no cure; treatment options are available to address some aspects, but none are specific to the neurological impairments of nGD.

GARDIAN is a global registry focused on patients with nGD. Through GARDIAN, the IGA aims to better understand the natural history of the disease and its impact on both patients and caregivers. As part of GARDIAN, disease specific patient-reported and observer-reported outcome scales will be developed.

Registry results will provide a comprehensive understanding of nGD which is essential to accelerate the early diagnosis and care for patients and ultimately improving patient outcomes. Real world evidence generated via GARDIAN will support clinical trial development and inform regulatory decision making.

“We’re excited to launch GARDIAN and wish to show our gratitude of our donors that are generously supporting this endeavor,” said Tanya Collin-Histed, CEO, International Gaucher Alliance. “The combined support of M6P Therapeutics; Pfizer; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company; and Sanofi Genzyme is a testament to the importance of GARDIAN and the difference it can make to our patient community.”

“We are delighted to partner with the IGA and our donors in an effort to help better understand neuronopathic Gaucher Disease and bring new therapies quicker to patients,” said Michael Fronstin, Global Head of Innovation, Real World Evidence, Kantar Health. “We welcome other organizations to contact us should they be interested in learning more or getting involved.”

Cerner Corporation (NASDAQ: CERN), a global healthcare technology company, acquired Kantar Health on April 1.

ABOUT THE INTERNATIONAL GAUCHER ALLIANCE (IGA)

The IGA is an international umbrella group representing the interests of Gaucher patients and those of not-for-profit Gaucher patient groups as well as rare disease groups throughout the world. While the IGA has an office in England, the IGA has almost 60 member associations around the globe. The GARDIAN registry will be under the control of International Gardian Limited (IGL), a wholly owned subsidiary of the IGA.

ABOUT KANTAR HEALTH

Kantar Health provides data, analytics and research to the life sciences industry. As real-world evidence and commercialization partners, Kantar Health enables clients to bring safe and effective treatment to patients around the world. The team has expertise across a myriad of therapy areas, including unique thought leadership in oncology and rare diseases. For more information on how to optimize commercial launch plans, demonstrate real-world effectiveness and safety, and build ongoing value substantiation to unlock your full potential, visit www.kantar.com/health.

Contacts

International Gaucher Alliance (IGA): [email protected]
Kantar Health: [email protected]